Sarepta Therapeutics | SRPT - 销售收入



金融业
股票价格
USD
资产
USD 3.18B
现金及等价物
USD 464.45M
销售成本
USD 109.46M
流动资产
USD 2.31B
流动负债
USD 499.16M
债务
USD 1.04B
EBIT
USD 358.43M
EBITDA
USD -252.2M
员工
1.37K
EPS每股收益
USD 3.16
股本和储备
USD 1.51B
销售毛利
USD 621.34M
债务利息支出
USD 20.84M
利息收入
USD 8.74M
贷款资金
USD 838.16M
市值
USD 1.41B
净收入
USD 330.96M
营业费用
USD 372.37M
营业利润
USD 358.43M
普通股股本
USD 105.57M
PE价格收益
27.27
税前利润
USD 343.17M
销售收入
USD 730.8M
销售和管理费用
USD 54.03M
股票
USD 1B
贸易债权人
USD 70.38M
应收帐款人
USD 547.91M


销售 更改 日
Acadia Pharmaceuticals USD 268.06M 15.94M 2026-03
Agios Pharmaceuticals USD 18.8M 1.17M 2026-03
Alnylam Pharmaceuticals USD 1.17B 70M 2026-03
Amgen USD 8.62B 1.28B 2026-03
BioCryst Pharmaceuticals USD 406.56M 247.16M 2025-12
Biogen USD 2.25B 30M 2026-03
BioMarin Pharmaceutical USD 766M 109M 2026-03
Capricor Therapeutics USD 11.13M 8.87M 2024-12
Daiichi Sankyo JPY 587B 28.89B 2026-03
Eli Lilly USD 19.8B 500M 2026-03
Esperion Therapeutics USD 168.45M 81.14M 2025-12
Gilead Sciences USD 7B 930M 2026-03
Incyte USD 1.27B 240M 2026-03
Insmed USD 305.96M 42.16M 2026-03
Ionis Pharmaceuticals USD 246M 43M 2026-03
Moderna USD 389M 289M 2026-03
Nektar Therapeutics USD 21.81M 2.32M 2025-12
Neurocrine Biosciences USD 811M 5.5M 2026-03
Novavax USD 147.14M 76.69M 2025-12
Pfizer USD 14.5B 3.08B 2026-03
PTC Therapeutics USD 273M 108.3M 2026-03
Regeneron Pharmaceuticals USD 3.6B 280M 2026-03
Roche Holding CHF 15.65B 274.5M 2025-12
Sangamo BioSciences USD 356K 125K 2024-06
Sanofi EUR 11.24B 60M 2026-03
Sarepta Therapeutics USD 730.8M 287.9M 2026-03
Tectonic Therapeutic USD 0 0 2024-12
Ultragenyx Pharmaceutical USD 136M 71M 2026-03
Vertex Pharmaceuticals USD 2.99B 200M 2026-03